Myriad myRisk® Hereditary Cancer tests for mutations in multiple genes associated with an increased risk for 8 different cancers. myRisk testing is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status and personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing.
3 out of 4 patients pay $0
Average turnaround time is 7-14 days
We make genetic testing simple for your patients and your practice
Multi-gene panel determines hereditary cancer risk associated with 8 cancer sites:
Clinically validated to predict both a woman’s 5-year, and remaining lifetime risk of developing breast cancer using genetic markers and clinical risk factors:
Test results are accompanied with the MMT which summarizes professional society guidelines for medical management based on patient’s individual results. Interventions are proven to reduce future risk of cancer
The riskScore precision medicine tool is clinically validated to predict a woman’s risk of developing breast cancer using clinical risk factors and genetic-markers. It provides women with their remaining lifetime and 5-year risk for developing breast cancer.
The myRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the myRisk Genetic Result and a personalized myRisk Management Tool based on professional medical society guidelines
In the largest validation study of its kind, Myriad estimated analytical sensitivity of greater than 99.92% with 100% concordance on NGS/Sanger parallel sequencing in all genes in the Myriad myRisk panel and 100% concordance on large rearrangement validation.
Commitment to Providing Broad Patient Access
Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families.
Variants Classified in 2016
Variants Re-classified in 2016
Amended Reports Issued in 2016
Myriad is dedicated, above all else, to improving patient care through pioneering research and the development of innovative molecular diagnostic tests. Since 1991, Myriad has invested more than a billion dollars to enhance the world’s collective scientific understanding of disease through collaborative research, outreach and education and to translate that knowledge into molecular and companion diagnostic tools that save and improve the lives of the patients we serve.
Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years
Invested in research over the past 5 years
Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.